Genetics of leflunomide for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This study looks at how your genes might affect how well leflunomide works for rheumatoid arthritis. It is for Pakistani adults who are starting or recently started leflunomide, and will help doctors understand who might respond best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 75 years old.
- You are of Pakistani origin.
- You have rheumatoid arthritis, diagnosed by standard criteria.
- You are either about to start leflunomide or have been taking it for less than a month.
- You are not taking any other disease-modifying anti-rheumatic drugs (DMARDs) at the same time.
- You do not have serious liver or kidney problems, active infections, inflammatory bowel disease, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
This trial tests whether leflunomide can safely help children with idiopathic pulmonary hemosiderosis (a condition where the lungs bleed, and iron builds up). The study is mainly about safety and early signs of benefit in young patients.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
Hear when a new Rhematoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.